The transition supports the company's Focused Innovator strategy, which prioritizes scaling neuroscience portfolios and integrating advanced digital capabilities into drug development. CEO Charl van Zyl noted that the move is essential for capturing growth opportunities and accelerating the delivery of treatments for brain-related diseases. By positioning its base near Cambridge, the firm intends to bridge internal R&D efforts with external academic and biotechnology partners.

Executive Vice President of R&D Tarek Samad emphasized that the region’s concentration of scientific and AI expertise provides a distinct advantage for refining the company's research pipeline. While the physical move represents a significant geographic change, leadership stated the primary objective is to maintain continuity for the existing US workforce, ensuring that current performance and patient services remain uninterrupted during the transition.